AV Therapeutics tackles next-gen prostate cancer therapy
By Catherine Shaffer
Wednesday, January 8, 2014
AV Therapeutics Inc. decloaked in late December by merging with a public shell company. It is developing a chemotherapy candidate, capridine, that has been shown in preclinical models to have activity against prostate and colon cancer, with plans to launch Phase I trials in the second quarter of 2014.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.